Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 850-860

  Fitzpatrick, Leo R ^a   Small, Jeffrey S ^a   Doblhofer, Robert ^b   Ammendola, Aldo ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b 4SC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; STAT3 PROTEIN; TRANSCRIPTION FACTOR; URIDINE; VIDOFLUDIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; COLITIS; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ANIMALS; ANTIGENS, CD3; BIPHENYL COMPOUNDS; CELL PROLIFERATION; COLITIS; COLON; DICARBOXYLIC ACIDS; FEMALE; HAPTENS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-23; NF-KAPPA B; RATS; RATS, WISTAR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID; URIDINE;

EID: 84865179094     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192203     Document Type: Article

References (35)

1. Bai A, Hu P, Chen J, Song X, Chen W, Peng W, Zeng Z, and Gao X (2007) Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis. Int J Colorectal Dis 22:625-635. (Pubitemid 47097033)
2. Bollrath J and Greten FR (2009) IKK/NF-κB and STAT3 pathways: central signaling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 10:1314-1319.
3. Chong AS, Huang W, Liu W, Luo J, Shen J, Xu W, Ma L, Blinder L, Xiao F, Xu X, et al. (1999) In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 68:100-109. (Pubitemid 29352839)
4. Danese S and Mantovani A (2010) Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 29:3313-3323.
5. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, and McGhee JR (1996) Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 157:2174-2185. (Pubitemid 126449698)
6. Fitzpatrick LR, Deml L, Hofmann C, Small JS, Groeppel M, Hamm S, Lemstra S, Leban J, and Ammendola A (2010a) 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm Bowel Dis 16:1763-1777.
7. Fitzpatrick LR, Green C, Maines LW, and Smith CD (2011a) Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosinekinase-2. Pharmacology 87:135-143.
8. Fitzpatrick LR, Meirelles K, Small JS, Puleo FJ, Koltun WA, and Cooney RN (2010b) A new model of chronic hapten-induced colitis in young rats. J Pediatr Gastroenterol Nutr 50:240-250.
9. Fitzpatrick LR, Small JS, and Ammendola A (2011b) Inhibition of IL-17 release by the novel anti-inflammatory drug vidofludimus involves attenuation of STAT3 and NF-κB signaling pathways in murine splenocytes and hapten-induced colitis. Gastroenterology 140:S837.
10. Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, and Koltun WA (2008) In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Br J Nutr 100:530-541.
11. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, and Kirschbaum BJ (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198-208.
12. Gao D, Wagner AH, Fankhaenel S, Stojanovic T, Schweyer S, Panzner S, and Hecker M (2005) CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 54:70-77. (Pubitemid 40007220)
13. Grivennikov SI and Karin M (2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21:11-19.
14. Hamm S, Henning SW, Hentsch B, Vitt D, Groeppel M, and Ammendola A (2012) Vidoludimus induces p53-mediated apoptosis in activated T cells and inhibits IL-17a and IL-17F expression decoupled from lymphocyte proliferation. J Crohns Colitis 6 (Suppl 1):S16.
15. He G and Karin M (2011) NF-κB and STAT3-key players in liver inflammation and cancer. Cell Res 21:159-168.
16. Herrlinger KR, Diculescu MM, Fellerman K, Hartmann H, Howaldt SM, Nikolov R, Petrov A, Reindl W, Otte JM, Stoinov S, et al. (2011) Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the entrance study. Gastroenterology 140:S588-S589.
17. Holtmann MH, Gerts AL, Weinman A, Galle PR, and Neurath MF (2008) Treatment of Crohn's disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. Dig Dis Sci 53:1025-1032. (Pubitemid 351379817)
18. Holtmann MH and Neurath MF (2006) From immunogenic mechanisms to novel therapeutic approaches in inflammatory bowel disease. Adv Exp Med Biol 579: 227-242.
19. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, Raskin L, Desai B, Faubion WA, de Waal Malefyt R, et al. (2009) Circulating and gut resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 206:525-534.
20. Kretzmann NA, Fillmann H, Mauriz JL, Marroni CA, Marroni N, González-Gallego J, and Tuñón MJ (2008) Effects of glutamine on proinflammatory gene expression and activation of nuclear factor κB and signal transducers and activators of transcription in TNBS-induced colitis. Inflamm Bowel Dis 14:1504-1513.
21. Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sárdy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, et al. (2010) 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas) Ipr mice. Am J Pathol 176:2840-2847.
22. Lanzarotto F, Carpani M, Chaudhary R, and Ghosh S (2006) Novel treatment options for inflammatory bowel disease: targeting α4 integrin. Drugs 66:1179-1189. (Pubitemid 44050434)
23. Morstyn G, Pyke K, Gardner J, Ashcroft R, de Fazio A, and Bhathal P (1986) Immunohistochemical identification of proliferating cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J Histochem Cytochem 34:697-701. (Pubitemid 16073400)
24. Nakase H, Okazaki K, Tabata Y, Uose S, Ohana M, Uchida K, Nishi T, Debreceni A, Itoh T, Kawanami C, et al. (2001) An oral drug delivery system targeting immuneregulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J Pharmacol Exp Ther 297:1122-1128. (Pubitemid 32472512)
25. Prajapati DN, Knox JF, Emmons J, Saeian K, Csuka ME, and Binion DG (2003) Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 37:125-128. (Pubitemid 36875571)
26. Reiss B and Williams GM (1979) Conditions affecting prolonged maintenance of mouse and rat colon in organ culture. In Vitro 15:877-890.
27. Reuter BK, Asfaha S, Buret A, Sharkey KA, and Wallace JL (1996) Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085. (Pubitemid 26376296)
28. Rückemann K, Fairbanks LD, Carrey EA, Hawrylowicz CM, Richards DF, Kirschbaum B, and Simmonds HA (1998) Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 273:21682-21691. (Pubitemid 28405342)
29. Strzȩpa A and Szczepanik M (2011) IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders. Pharmacol Rep 63:30-44.
30. Sutton C, Brereton C, Keogh B, Mills KH, and Lavelle EC (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med 203:1685-1691. (Pubitemid 44036274)
31. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, and Mills KH (2009) Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells amplifying Th17 responses and autoimmunity. Immunity 31:331-341.
32. Tanabe S, Kinuta Y, and Saito Y (2008) Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. Int J Mol Med 22:181-185.
33. Wittig BM, Johansson B, Zöller M, Schwärzler C, and Günthert U (2000) Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 191:2053-2064.
34. Youn J, Lee JS, Na HK, Kundu JK, and Surh YJ (2009) Resveratol and piceatannol inhibit iNOS expression and NF-κB activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer 61:847-854.
35. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, and Kolls JK (2006) Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 12:382-388.